ABIVAX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.7 EUR | +1.28% |
|
+1.93% | +29.33% |
| May. 20 | BTIG Initiates Abivax at Buy Rating With $43 Price Target | MT |
| May. 08 | Abivax: four abstracts to be presented on obefazimod | CF |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 265.2 | 475.9 | 467.2 | 103.7 | 615.2 | 799.1 | - | - |
| Enterprise Value (EV) 1 | 276.6 | 446.6 | 406.5 | 76.71 | 439.9 | 672.1 | 742.7 | 563.7 |
| P/E ratio | -8.98 x | -13.1 x | -11.6 x | -1.97 x | -2.86 x | -5.1 x | -4.51 x | -4.61 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 280 x | 48.2 x | 1,037 x | 134 x | 260 x | 319 x | 128 x |
| EV / Revenue | - | 263 x | 41.9 x | 767 x | 95.6 x | 219 x | 296 x | 90.2 x |
| EV / EBITDA | -8.33 x | -11.8 x | -9.59 x | -1.36 x | -3.47 x | -4.96 x | -4.37 x | -3.05 x |
| EV / FCF | -9.74 x | -14.5 x | -8.59 x | -1.16 x | -4.52 x | -4.97 x | -4.74 x | -3.51 x |
| FCF Yield | -10.3% | -6.88% | -11.6% | -85.9% | -22.1% | -20.1% | -21.1% | -28.5% |
| Price to Book | - | - | 13.4 x | 15.8 x | 3.15 x | 11 x | -6.83 x | -2.51 x |
| Nbr of stocks (in thousands) | 11,762 | 13,834 | 16,363 | 16,774 | 62,646 | 62,918 | - | - |
| Reference price 2 | 22.55 | 34.40 | 28.55 | 6.180 | 9.820 | 12.70 | 12.70 | 12.70 |
| Announcement Date | 3/16/20 | 3/31/21 | 3/16/22 | 4/19/23 | 4/2/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1.7 | 9.7 | 0.1 | 4.6 | 3.072 | 2.508 | 6.248 |
| EBITDA 1 | -33.22 | -37.94 | -42.4 | -56.57 | -126.7 | -135.6 | -170.1 | -185 |
| EBIT 1 | -33.3 | -38 | -42.6 | -56.6 | -127.4 | -149.4 | -179.5 | -196.5 |
| Operating Margin | - | -2,235.29% | -439.18% | -56,600% | -2,769.57% | -4,861.68% | -7,156.11% | -3,145.53% |
| Earnings before Tax (EBT) 1 | -34.9 | -40.1 | -45.6 | -74.32 | -147.7 | -157.7 | -179.1 | -210.2 |
| Net income 1 | -30.6 | -37.6 | -41.4 | -69.8 | -147.4 | -157.8 | -179.5 | -203.4 |
| Net margin | - | -2,211.76% | -426.8% | -69,800% | -3,204.35% | -5,136.46% | -7,157.7% | -3,255.89% |
| EPS 2 | -2.510 | -2.620 | -2.470 | -3.130 | -3.430 | -2.490 | -2.817 | -2.755 |
| Free Cash Flow 1 | -28.41 | -30.72 | -47.3 | -65.88 | -97.4 | -135.2 | -156.7 | -160.8 |
| FCF margin | - | -1,807.12% | -487.62% | -65,885% | -2,117.28% | -4,399.64% | -6,246.06% | -2,573.48% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/31/21 | 3/16/22 | 4/19/23 | 4/2/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 S1 | 2023 S1 | 2023 S2 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 | 2025 Q1 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 2.4 | 1.123 | 1.123 | 1.967 | 1.123 | 1.123 | 1.967 | 1.123 | 1.3 | 1.3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -18.6 | - | - | -32.13 | -32.13 | -90.7 | -32.13 | -32.13 | -96 | -32.39 | -91 | -93.8 |
| Operating Margin | - | - | - | -2,861.44% | -2,861.44% | -4,611.86% | -2,861.44% | -2,861.44% | -4,881.35% | -2,884.59% | -7,000% | -7,215.38% |
| Earnings before Tax (EBT) 1 | - | - | - | -32.13 | -32.13 | -101.6 | -32.13 | -32.13 | -109.6 | -32.39 | - | - |
| Net income 1 | -29.6 | -51.95 | -95.4 | -32.13 | -32.13 | -93.57 | -32.13 | -32.13 | -99.87 | -32.39 | -91 | -93.8 |
| Net margin | - | - | -3,975% | -2,861.44% | -2,861.44% | -4,757.62% | -2,861.44% | -2,861.44% | -5,077.96% | -2,884.59% | -7,000% | -7,215.38% |
| EPS | - | -1.450 | - | - | - | -1.620 | - | - | -1.540 | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 9/15/22 | 9/29/23 | 4/2/24 | - | - | - | - | - | - | - | - | - |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 11.4 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 29.3 | 60.7 | 27 | 175 | 127 | 56.4 | 235 |
| Leverage (Debt/EBITDA) | -0.3432 x | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -28.4 | -30.7 | -47.3 | -65.9 | -97.4 | -135 | -157 | -161 |
| ROE (net income / shareholders' equity) | - | - | - | - | -145% | -112% | -202% | -122% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 2.130 | 0.3900 | 3.120 | 1.150 | -1.860 | -5.060 |
| Cash Flow per Share 2 | -2.400 | -2.170 | -2.820 | -2.940 | - | -2.200 | -2.100 | - |
| Capex 1 | 0.94 | 0.9 | 1.64 | 0.31 | 0.27 | 1.58 | 1.5 | 2 |
| Capex / Sales | - | 52.82% | 16.93% | 306% | 5.76% | 51.26% | 59.8% | 32.01% |
| Announcement Date | 3/16/20 | 3/31/21 | 3/16/22 | 4/19/23 | 4/2/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.7
EUR
Average target price
36.34
EUR
Spread / Average Target
+186.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.33% | 871M | |
| +22.10% | 46.55B | |
| +46.45% | 41.84B | |
| -3.12% | 40.84B | |
| +36.10% | 32.95B | |
| -6.30% | 28.27B | |
| +18.71% | 27.78B | |
| +46.15% | 14.26B | |
| +44.52% | 13.69B | |
| +0.19% | 12.18B |
- Stock Market
- Equities
- ABVX Stock
- Financials Abivax
